Tavulus® is expected to provide relief to a large patient population in the country. It is a long-acting bronchodilator
Key Point –
- Tiotropium DPI had a market size of US$ 433 Mn in the EU in the 12-month period ended March 2021 (IQVIA data)
- Glenmark Pharma launches dry powder for the treatment of COPD in Spain
- Tavulus® is Glenmark’s bioequivalent version of Boehringer Ingelheim’s Spiriva® Handihaler®
- The launch is part of a wider Glenmark’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK.
COPD is a long-term condition that causes inflammation in the lungs, damaging the lung tissue and narrowing the airways, all of which make breathing difficult. Glenmark will sell the powder under the brand name Tavulus.
Drug company Glenmark Pharmaceuticals Limited launched a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) to treat chronic obstructive pulmonary disease (COPD) in Spain.
COPD is a long-term condition that causes inflammation in the lungs, damaging the lung tissue and narrowing the airways, all of which make breathing difficult. Glenmark will sell the powder under the brand name Tavulus.
Studies show that close to 2.5 million people suffer from COPD in Spain. Glenmark claims that Tavulus will provide relief to a large patient population by working as a long-acting bronchodilator that helps open the airways and makes it easier for air to get in and out of the lungs. It prevents sudden, short-term worsening of COPD symptoms.
“The goal of COPD treatment has always been to provide quick symptomatic relief to patients and reduce the risk of exacerbations. Since its launch, we have seen the multiple therapeutic benefits of Tavulus in other markets and are pleased to extend these benefits to patients in Spain. This inhalation therapy shows to aid in the daily management of COPD significantly. We hope that it improves both COPD symptoms and quality of life in those who are most affected,” said Dr Jiří Havránek, Vice President, Business Development of Glenmark Pharmaceuticals Limited.
In November 2017, a Glenmark European subsidiary entered into a strategic, exclusive in-licensing arrangement for marketing generic Tiotropium Bromide DPI in Western Europe and the UK. Glenmark is planning subsequent launches of the product across these markets under the brand name Tiogiva in the UK, Ireland, Sweden, Finland, and Norway; Tavulus in Denmark and Netherlands; and Tiotropium Glenmark in Germany.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with a presence across generics, specialty, and over-the-counter (OTC) businesses with operations in over 50 countries.
The pharmaceutical company posted a 20.7% rise in consolidated net profit to Rs 306.53 crore on a 27.6% increase in net sales to Rs 2,946 crore in Q1 FY22 over Q1 FY21.
Shares of Glenmark Pharmaceuticals closed 1.85% higher at Rs 526.80 on Friday.
Future Plans
Glenmark is planning subsequent launches of the product across these markets under the brand name Tiogiva® in the UK, Ireland, Sweden, Finland, and Norway; Tavulus® in Denmark and Netherlands; and Tiotropium Glenmark® in Germany.